Xylem said Q3 2025 revenue was $2.3 billion, up 8% on a reported basis and 7% organically. Revenue for Q3 was $2,268 million compared with $2,104 million in the prior-year quarter, according to the income statement.

1. 01

   Xylem said Q3 2025 revenue was $2.3 billion, up 8% on a reported basis and 7% organically. Revenue for Q3 was $2,268 million compared with $2,104 million in the prior-year quarter, according to the income statement.

2. 02

   The company said net income attributable to Xylem for Q3 was $227 million, or $0.93 per share, with net income margin declining 30 basis points to 10.0%. It attributed the results to strong operational performance and decreased interest expense, offset by increased loss from the sale of businesses and higher tax expense.

3. 03

   Xylem said adjusted EBITDA margin for Q3 was 23.2%, up 200 basis points from the prior-year quarter. Adjusted net income was $333 million and adjusted earnings per share was $1.37, excluding the impacts of loss from the sale of businesses, restructuring and realignment costs and other items.

4. 04

   The company provided full-year revenue guidance of approximately $9.0 billion, up 5 to 6% on a reported basis compared with prior guidance of 4 to 5%, and adjusted earnings per share of $5.03 to $5.08 versus the previous guide of $4.70 to $4.85. Full-year free cash flow margin is expected to be approximately 9 to 10%.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.